Subscribe for full access
Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Recommendation Rating
2
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 5.67
Low: 4.7
High: 6.64
Total Analysts: 3
Company Profile
Arecor Therapeutics plc is a globally focused biopharmaceutical company. The Company, through its formulation technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver formulations of their therapeutic products. Its clinical development programs include AT247-Ultra-Rapid Acting Insulin and AT278-Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. AT278 is a concentrated formulation of rapid acting insulin that is designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. It also has Tetris Pharma portfolio.
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.
